Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Wei Peng, Yangxun Pan, Lan Xie, Zhoutian Yang, Zhiwei Ye, Jinbin Chen, Juncheng Wang, Dandan Hu, Li Xu, Zhongguo Zhou, Minshan Chen, Aiping Fang, Yaojun Zhang
BACKGROUND: Given the superior performance of various therapies over sorafenib in advanced hepatocellular carcinoma (HCC) and the absence of direct comparisons, it is crucial to explore the efficacy of these treatments in phase III randomized clinical trials. OBJECTIVES: The goal is to identify which patients are most likely to benefit significantly from these emerging therapies, contributing to more personalized and informed clinical decision-making. DESIGN: Systematic review and network meta-analysis...
2024: Therapeutic Advances in Gastroenterology
#2
JOURNAL ARTICLE
Hui Wang, Caiyun Nie, Weifeng Xu, Jing Li, He Gou, Huifang Lv, Beibei Chen, Jianzheng Wang, Yingjun Liu, Yunduan He, Jing Zhao, Xiaobing Chen
BACKGROUND: For patients with human epidermal growth factor receptor-2 (HER2)-positive advanced or metastatic gastric cancer who have progressed on first-line trastuzumab therapy, the clinical value of the continuous use of trastuzumab beyond progression (TBP) is controversial. OBJECTIVES: The present study was conducted to evaluate the efficacy and explore new treatment strategies of TBP for patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer in the era of cancer immunotherapy...
2024: Therapeutic Advances in Gastroenterology
#3
JOURNAL ARTICLE
Anthony J Lembo, Susan Edelstein, David P Rosenbaum, Ceciel Rooker, Jeffrey D Roberts, William D Chey
No abstract text is available yet for this article.
2024: Therapeutic Advances in Gastroenterology
#4
REVIEW
Meiling Liu, Siyi Guo, Liang Wang
BACKGROUND: Despite numerous metabolomic studies on ulcerative colitis (UC), the results have been highly variable, making it challenging to identify key metabolic abnormalities in UC. OBJECTIVES: This study aims to uncover key metabolites and metabolic pathways in UC by analyzing existing metabolomics data. DESIGN: A systematic review. DATA SOURCES AND METHODS: We conducted a comprehensive search in databases (PubMed, Cochrane Library, Embase, and Web of Science) and relevant study references for metabolomic research on UC up to 28 December 2022...
2024: Therapeutic Advances in Gastroenterology
#5
JOURNAL ARTICLE
Ming-Ling Chang, Jur-Shan Cheng, Puo-Hsien Le, Wei-Ting Chen, Hsin-Ping Ku, Rong-Nan Chien
BACKGROUND: How antimitochondrial antibody (AMA)-positive patients evolve to have primary biliary cholangitis (PBC) in viral hepatitis-endemic areas is unknown. OBJECTIVES: We aimed to investigate this evolution in Taiwan. DESIGN/METHODS: A 16-year medical center-based cohort study of 2,095,628 subjects was conducted in Taiwan, an Asian country endemic to viral hepatitis. AMA-positive subjects were those with positive AMA with alkaline phosphatase (ALP) ⩽1...
2024: Therapeutic Advances in Gastroenterology
#6
JOURNAL ARTICLE
Whitfield L Knapple, David S Yoho, Alexander Sheh, Joan Thul, Paul Feuerstadt
BACKGROUND: Fecal microbiota, live-jslm (RBL; REBYOTA® ), is the first Food and Drug Administration (FDA)-approved, single-dose, rectally administered, microbiota-based live biotherapeutic product for preventing Clostridioides difficile infection (CDI) recurrence. Alternative routes of administration are of clinical interest. OBJECTIVES: Evaluate the safety and efficacy of RBL administration via colonoscopy. DESIGN: Retrospective analysis of electronic medical records of participants administered RBL via colonoscopy under FDA enforcement discretion...
2024: Therapeutic Advances in Gastroenterology
#7
JOURNAL ARTICLE
Péter Bacsur, Panu Wetwittayakhlang, Tamás Resál, Emese Földi, Béla Vasas, Bernadett Farkas, Mariann Rutka, Talat Bessissow, Waqqas Afif, Anita Bálint, Anna Fábián, Renáta Bor, Zoltán Szepes, Klaudia Farkas, Peter L Lakatos, Tamás Molnár
BACKGROUND: Different endoscopic scoring systems for assessing ulcerative colitis (UC) severity are available. However, most of them are not correlated with disease extent. OBJECTIVES: Our study aimed to compare the predictive value of the PanMay score versus the endoscopic Mayo (MES), Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and Dublin score in predicting long-term outcomes of UC. DESIGN: This retrospective study enrolled consecutive UC patients who underwent colonoscopy before at least a 3-year follow-up...
2024: Therapeutic Advances in Gastroenterology
#8
JOURNAL ARTICLE
Andrea Pasta, Filippo Pelizzaro, Elisa Marabotto, Francesco Calabrese, Elena Formisano, Shirin Djahandideh Sheijani, Giovanni Brandimarte, Giampiero Manes, Antonietta Gerarda Gravina, Edoardo Vincenzo Savarino
BACKGROUND: Gastroesophageal reflux disease (GERD) is a challenging condition that involves different physicians, such as general practitioners (GPs), gastroenterologists, and ears, nose and throat (ENT) specialists. A common approach consists of proton-pump inhibitors (PPIs) administration. Adjunctive pharmacological treatment may have a role in the management of non-responders to PPIs. OBJECTIVES: We aimed to survey GPs and different medical specialists to investigate the medical approaches to patients reporting GERD symptoms...
2024: Therapeutic Advances in Gastroenterology
#9
JOURNAL ARTICLE
Oliver Bjurström, Pontus Karling
BACKGROUND: Smoking and the use of non-steroidal anti-inflammatory drugs (NSAIDs) acetylsalicylic acid (ASA), proton pump inhibitors (PPIs), serotonin reuptake inhibitors (SSRIs), and statins have been associated with microscopic colitis (MC). OBJECTIVES: We investigated whether these factors were associated with repeated budesonide treatments in patients diagnosed with MC. DESIGN: Retrospective observational study. METHODS: All patients with a histologically verified diagnosis of MC at our clinic between the years 2006 and 2022 were identified...
2024: Therapeutic Advances in Gastroenterology
#10
JOURNAL ARTICLE
Dongwook Oh, Sung Yong Han, Sang Hyub Lee, Seong-Hun Kim, Woo Hyun Paik, Hyung-Ku Chon, Tae Jun Song, Se Woo Park, Jae Hee Cho
BACKGROUND: Endoscopic ultrasound-guided biliary drainage (EUS-BD), classified as choledochoduodenostomy (CDS) and hepaticogastrostomy (HGS), is a feasible and effective alternative for distal malignant biliary obstruction (MBO) in failed endoscopic retrograde cholangiopancreatography. However, the preferred technique for better outcomes has not yet been evaluated. OBJECTIVES: We compared the long-term outcomes between the techniques. DESIGN: Retrospective comparative study...
2024: Therapeutic Advances in Gastroenterology
#11
JOURNAL ARTICLE
Anuj Bohra, Nicholas Batt, Krishneel Dutt, Diana Lewis, Jonathan P Segal, Olga Newiadomski, Abhinav Vasudevan, Daniel R Van Langenberg
BACKGROUND: Faecal biomarkers are increasingly utilized for disease assessment in inflammatory bowel disease (IBD). OBJECTIVES: To characterize the relative and combined accuracy of faecal calprotectin (FC) and faecal immunochemical testing (FIT) for detecting endoscopic and histologically active disease in Crohn's disease (CD) and ulcerative colitis (UC), subdivided by disease location. DESIGN: A prospective cohort study. METHODS: Patients with confirmed IBD undergoing routine ileocolonoscopy for activity assessment were prospectively recruited and performed both FC and FIT ±30 days of ileocolonoscopy...
2024: Therapeutic Advances in Gastroenterology
#12
JOURNAL ARTICLE
Minghui Liu, Ning Wei, Yuhu Song
OBJECTIVES: Left-sided portal hypertension (LSPH) leads to life-threatening gastrointestinal (GI) bleeding. There are no recommendations or consensus about the management of GI bleeding caused by LSPH. This systematic review and meta-analysis were conducted to evaluate the incidence of GI bleeding and the mortality of patients with LSPH receiving different therapeutic strategies. DESIGN: A systematic review and meta-analysis were performed to determine the efficacy of different therapeutic strategies for GI bleeding caused by LSPH...
2024: Therapeutic Advances in Gastroenterology
#13
JOURNAL ARTICLE
Brian E Lacy, Régis Delfini, Bernward Fladung, Robert Lange
BACKGROUND: Constipation is characterized by symptoms of straining, hard stool, difficult evacuation, and infrequent bowel movements. Online surveys provide valuable information about patients' perspectives, symptoms, management, treatment satisfaction, and risk factors. METHODS: This survey explored subject experiences involving 20 gastrointestinal (GI) conditions. In total, 20,099 respondents in seven countries with varied cultural and socioeconomic backgrounds participated...
2024: Therapeutic Advances in Gastroenterology
#14
JOURNAL ARTICLE
Francisco Mesonero, Yamile Zabana, Agnès Fernández-Clotet, Eduardo Leo-Carnerero, Berta Caballol, Andrea Núñez-Ortiz, María José García, Federico Bertoletti, Alejandro Mínguez, Gerard Suris, Begoña Casis, Rocío Ferreiro-Iglesias, Margalida Calafat, Itxaso Jiménez, José Miranda-Bautista, Luis Javier Lamuela, Ingrid Fajardo, Leyanira Torrealba, Rodrigo Nájera, Rosa María Sáiz-Chumillas, Irene González, Miren Vicuña, Natalia García-Morales, Ana Gutiérrez, Alicia López-García, José Manuel Benítez, Cristina Rubín de Célix, Coral Tejido, Eduard Brunet, Alejandro Hernández-Camba, Cristina Suárez, Iago Rodríguez-Lago, Marta Piqueras, Andrés Castaño, Laura Ramos, Ana Sobrino, María Carmen Rodríguez-Grau, Alfonso Elosua, Miguel Montoro, Ruth Baltar, José María Huguet, Benito Hermida, Antonio Caballero-Mateos, Luis Sánchez-Guillén, Abdel Bouhmidi, Ramón Pajares, Iria Baston-Rey, Antonio López-Sanromán, Agustin Albillos, Manuel Barreiro-de Acosta
BACKGROUND: The usefulness of thiopurines has been poorly explored in pouchitis and other pouch disorders. OBJECTIVE: To evaluate the effectiveness and safety of azathioprine as maintenance therapy in inflammatory pouch disorders. DESIGN: This was a retrospective and multicentre study. METHODS: We included patients diagnosed with inflammatory pouch disorders treated with azathioprine in monotherapy. Effectiveness was evaluated at 1 year and in the long term based on normalization of stool frequency, absence of pain, faecal urgency or fistula discharge (clinical remission), or any improvement in these symptoms (clinical response)...
2024: Therapeutic Advances in Gastroenterology
#15
REVIEW
Shixian Liu, Lei Dou, Shunping Li
BACKGROUND: Recently, several novel programmed cell death protein 1 (PD-1) inhibitors have been approved for second-line treating advanced or metastatic oesophageal squamous cell carcinoma (OSCC), including camrelizumab, nivolumab, pembrolizumab, sintilimab and tislelizumab. However, the optimal treatment regimen remained ambiguous. OBJECTIVES: The purpose of this study was to investigate the efficacy, safety and economy of available PD-1 inhibitors to determine the optimal treatment from the Chinese healthcare system perspective...
2024: Therapeutic Advances in Gastroenterology
#16
JOURNAL ARTICLE
Brendan P Halloran, Matthew Reeson, Christopher Teshima, Karen Kroeker, Vivian Huang, Levinus Dieleman, Peter Holmes, Daniel C Baumgart, Karen Wong, Frank Hoentjen, Farhad Peerani, Sergio Zepeda-Gomez
BACKGROUND: Despite recent emerging literature involving the utility of endoscopic balloon dilation (EBD) of strictures via balloon-assisted endoscopy (BAE), specifically regarding the management of Crohn's disease (CD), the optimal clinical approach with balloon systems has been largely neglected in academic literature. OBJECTIVES: This study assesses the intra-procedural success and safety of EBD via BAE for small bowel CD strictures while detailing our clinical approach and technique...
2024: Therapeutic Advances in Gastroenterology
#17
JOURNAL ARTICLE
Penglei Ge, Yang Wu
No abstract text is available yet for this article.
2024: Therapeutic Advances in Gastroenterology
#18
JOURNAL ARTICLE
Suzanne I Anjie, Krisztina B Gecse, Cyriel Y Ponsioen, Mark Löwenberg, Geert R D'Haens
Subcutaneous vedolizumab has demonstrated efficacy as a maintenance therapy in inflammatory bowel disease (IBD). However, data on the extension of subcutaneous vedolizumab injection intervals are lacking. Here, we present the first real-world data on subcutaneous vedolizumab interval extension in IBD patients. Nine patients (eight Crohn's disease patients and one ulcerative colitis patient) were included in the study. At interval extension (at baseline), all patients were in clinical and biochemical remission and requested an extension of their 2-weekly injection intervals due to side effects potentially related to subcutaneous vedolizumab...
2024: Therapeutic Advances in Gastroenterology
#19
REVIEW
Chao Han, Yan-Wei Lv, Liang-Hao Hu
As a progressive fibroinflammatory disease, chronic pancreatitis (CP) often manifests as recurrent bouts of abdominal pain with or without complications, causing a heavy burden of health care. In recent years, some meaningful insights into the management of CP have been obtained from randomized controlled trials, systematic reviews, and meta-analyses, which were of great importance. Based on this research, it is shown that there are various treatments for CP. Therefore, it is of great importance to choose a suitable strategy for patients with CP individually...
2024: Therapeutic Advances in Gastroenterology
#20
JOURNAL ARTICLE
Gaurav B Nigam, Kelly Chatten, Ala Sharara, Talal Al-Taweel, Othman Alharbi, Hussein Elamin, Sameer Al Awadhi, Vito Annese, Jimmy K Limdi
BACKGROUND: A growing body of evidence underscores the beneficial impact of therapeutic drug monitoring (TDM) on the efficacy and cost-effectiveness of anti-tumour necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD). OBJECTIVES: We surveyed clinician attitudes, perceptions and barriers related to TDM in IBD in the Middle East. DESIGN: A 15-question survey was distributed through national gastroenterological societies in five Middle Eastern countries (UAE, Saudi Arabia, Kuwait, Lebanon and Egypt)...
2024: Therapeutic Advances in Gastroenterology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
